

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## REVISED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
WO 02/062947 A2

(51) International Patent Classification<sup>7</sup>: C07K 14/72

(21) International Application Number: PCT/US01/50204

(22) International Filing Date: 20 October 2001 (20.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/241,881 20 October 2000 (20.10.2000) US

(71) Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL [—US]; Department of Medicine, P.O. Box 2688, New Brunswick, NJ 08903-2688 (US).

(72) Inventor: PRANELA, Rameshwar; 217 Lexington Avenue, Maplewood, NJ 07040 (US).

(74) Agent: WISE, Michael, J.; Lyon & Lyon LLP, Perkins Coie LLP, P.O. Box 1208, Seattle, WA 98111-1208 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority

(48) Date of publication of this revised version:  
24 December 2003

(15) Information about Corrections:  
see PCT Gazette No. 52/2003 of 24 December 2003, Section II  
Previous Correction:  
see PCT Gazette No. 04/2003 of 23 January 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/062947 A2

(54) Title: HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 GENE

(57) Abstract:

PATENT COOPERATION TREATY

PCT

DECLARATION OF NON-ESTABLISHMENT OF INTERNATIONAL SEARCH REPORT

(PCT Article 17(2)(a), Rules 13ter.1(c) and Rule 39)

Applicant's or agent's file reference	IMPORTANT DECLARATION	Date of mailing(day/month/year) 30/09/2003
International application No. PCT/US 01/ 50204	International filing date(day/month/year) 20/10/2001	(Earliest) Priority date(day/month/year) 20/10/2000
International Patent Classification (IPC) or both national classification and IPC		C07K14/72
Applicant UNIVERSITY OF MEDICINE AND DENTISTRY--NEW...		

This International Searching Authority hereby declares, according to Article 17(2)(a), that no international search report will be established on the international application for the reasons indicated below

1.  The subject matter of the international application relates to:
  - a.  scientific theories.
  - b.  mathematical theories
  - c.  plant varieties.
  - d.  animal varieties.
  - e.  essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes.
  - f.  schemes, rules or methods of doing business.
  - g.  schemes, rules or methods of performing purely mental acts.
  - h.  schemes, rules or methods of playing games.
  - i.  methods for treatment of the human body by surgery or therapy.
  - j.  methods for treatment of the animal body by surgery or therapy.
  - k.  diagnostic methods practised on the human or animal body.
  - l.  mere presentations of information.
  - m.  computer programs for which this International Searching Authority is not equipped to search prior art.
2.  The failure of the following parts of the international application to comply with prescribed requirements prevents a meaningful search from being carried out:
 

the description       the claims       the drawings
3.  The failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions prevents a meaningful search from being carried out:
 

the written form has not been furnished or does not comply with the standard.

the computer readable form has not been furnished or does not comply with the standard.
4. Further comments: see next page

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Anna Sjöberg 
---	--

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 203

The claims of the underlying application have, according to PCT Rule 13ter.1.c, not been searched since the Sequence Listing as present in the description does not comply with WIPO Standard ST 25 prescribed in the administrative instructions under Rule 5.2. The Sequence Listing has not been furnished in machine readable form as provided for in the same instructions and the applicant has not remedied the disclosed deficiencies within the time limit fixed in the invitation pursuant to PCT Rule 13ter.1.a.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

